Early stroke detection
Cerebrovascular diseases are the third most common Causes of death worldwide. According to an official statement by the WHO up to six million people die from it every year. However, up to now there is no reliable biomarker which can detect a stroke at an early stage.
Diagenics has developed a method that makes it possible power to measure strokes using a biomarker: Glycogen Phosphorylase Isoenzyme BB (GPBB). This enzyme is specific for the heart and the brain, which in the case of ischemia released into the bloodstream becomes - much earlier than all necrosis markers.
RISK FACTORS:HIGH BLOOD PRESSURE UNHEALTHY LIFESTYLE OVERWEIGHT GENETIC CONDITIONS
Diagenics has patented antibodies to this Enzyme and already has a new line of products for early diagnosis Developed from strokes: DIASTROKE®. The product was made based on the above Study CE registered. Future studies will be ours Expertise in the field of stroke diagnosis expand.